I kontrollerede, kliniske forsøg var incidensen af diarré hos Rasilez HCT- behandlede patienter 1, 3%, sammenlignet med 1, 4% for aliskiren - eller 1, 9% for hydrochlorthiazidbehandlede patienter.
In controlled clinical trials, the incidence of diarrhoea in Rasilez HCT-treated patients was 1.3% compared to 1.4% for aliskiren- or 1.9% for hydrochlorothiazide-treated patients.